These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34556001)

  • 1. Advances and challenges in nintedanib drug delivery.
    Velagacherla V; Suresh A; Mehta CH; Nayak UY
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1687-1706. PubMed ID: 34556001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the development of asenapine formulations.
    Suresh A; Narayan R; Nayak UY
    Expert Opin Drug Deliv; 2020 Oct; 17(10):1377-1393. PubMed ID: 32633149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.
    Umemura Y; Mitsuyama Y; Minami K; Nishida T; Watanabe A; Okada N; Yamakawa K; Nochioka K; Fujimi S
    Int J Infect Dis; 2021 Jul; 108():454-460. PubMed ID: 34048887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
    Fukihara J; Kondoh Y
    Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Cottin V
    Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
    Dimitroulis IA
    Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
    Valenzuela C; Torrisi SE; Kahn N; Quaresma M; Stowasser S; Kreuter M
    Respir Res; 2020 Jan; 21(1):7. PubMed ID: 31906942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?
    Duarte AC; Santos MJ; Cordeiro A
    Clin Rheumatol; 2018 Apr; 37(4):1123-1127. PubMed ID: 29038968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
    Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
    Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nintedanib on the microvascular architecture in a lung fibrosis model.
    Ackermann M; Kim YO; Wagner WL; Schuppan D; Valenzuela CD; Mentzer SJ; Kreuz S; Stiller D; Wollin L; Konerding MA
    Angiogenesis; 2017 Aug; 20(3):359-372. PubMed ID: 28283856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.